Oncology

Lifileucel elicited objective responses, including complete responses, for a median duration that was not yet reached at 28.1 months for patients with advanced melanoma.

Nina Shah, MD, discusses the management of CAR T-cell therapy–related toxicities in multiple myeloma.

As more therapies continue to be approved, efforts will focus on toxicity prevention and mitigation strategies for associated unique and potentially life-threatening adverse reactions.

The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Nina Shah, MD, discusses the potential rationale for selecting between the investigational CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

The tumor infiltrating lymphocyte therapy LN-145 was feasible, safe, and effective in patients with pretreated advanced cervical cancer.

Kenneth C. Anderson, MD, discusses potentially addressing unmet needs in patients with multiple myeloma through the use of the mRNA-based CAR T-cell therapy Descartes-11.

The FDA has granted a fast track designation to the placental-derived natural killer cell therapy CYNK-001 as a potential treatment for adult patients with recurrent glioblastoma multiforme.

Omidubicel significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with hematologic malignancies.

The modified red blood cell therapy RTX-240 demonstrated promising efficacy and a favorable safety profile in patients with relapsed/refractory solid tumors.

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Sattva Neelapu, MD, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Sattva Neelapu, MD, discusses emerging CAR T-cell therapies for patients with relapsed/refractory mantle cell lymphoma.

AbbVie and Caribou Biosciences, Inc have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor T-cell therapeutics.

An independent board has determined that ofranergene obadenovec is safe allowing the phase 3 OVAL study to continue.

Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.

Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.

Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.

A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays.

Binod Dhakal, MD, discusses the differences in onset of cytokine release syndrome with CAR T-cell therapies in multiple myeloma.

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.

Readers favored news about ibrutinib, the first chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma, and the effect of the pandemic on patients with chronic lymphocytic leukemia.

Yi Lin, MD, PhD, discusses the promise of the CAR T-cell products ciltacabtagene autoleucel and idecabtagene vicleucel in patients with myeloma.

December 21, 2020 - A rolling submission of the biologics license application for the BCMA-directed CAR T-cell product ciltacabtagene autoleucel for use in adults with relapsed/refractory multiple myeloma has been initiated to the FDA.

The findings help explain why costly CAR T-cell therapy does not work for some patients.

A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.